For preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma, usage of serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 may be helpful. Additionally, the prognosis of the patients with gastric adenocarcinoma treated with gastrectrectomy may be associated with serum and peritoneal levels of tumor markers.
Clinical usage of tumor markers on preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma is a controversial issue. It has been thought that there is a positive correlation between serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 and pathologic features of gastric tumors and peritoneal dissemination. In this study, it was aimed to evaluate the effect of serum and peritoneal CEA and CA 19-9 to predict TNM stages and peritoneal washing cytology in patients with gastric adenocarcinoma after curative gastrectomy, and to determine predictive value of these measurements to the development of recurrence and death.
Study Type
OBSERVATIONAL
Enrollment
67
radical total/subtotal gastrectomy with D2 lymph node dissection
After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
Mustafa Hasbahceci
Istanbul, Turkey (Türkiye)
TNM stage
TNM stage based on the 7th American Joint Committee on Cancer/International Union Against Cancer tumor, node, metastasis system.
Time frame: through pathologic report completion, an average of 1 month
peritoneal washing cytology
detection of positive free peritoneal gastric adenocarcinoma cells.
Time frame: through pathologic report completion, an average of 1 month
recurrence/death
detection of recurrence or development of death
Time frame: through follow-up period, an average of 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.